Ceramides as Biomarkers of Risk Prediction and Prognosis in Cardiovascular and Other Diseases: Are We There Yet?
- 1Cardiovascular Innovation Laboratory, The Helen B. Taussig Center, Division of Cardiology, Department of Pediatrics, School of Medicine, Johns Hopkins University, Baltimore, MD 21287, USA
Abstract
Cardiovascular disease (CVD) is the leading cause of death worldwide, yet roughly 70% of major adverse cardiovascular events occur in statin-treated patients with optimized Low-density lipoprotein cholesterol (LDL-C), a gap that cholesterol-based risk panels do not close. Ceramides are bioactive sphingolipids whose plasma species and ratios carry risk information absent from standard lipid panels, and ceramide-based scores (CERT and CERT2) are already in clinical use. Whether this value extends beyond CVD is unclear. We reviewed ceramide species and ratios as biomarkers for disease prediction, prognosis, and disease activity across cardiovascular, metabolic, autoimmune rheumatic, inflammatory bowel, pulmonary, kidney, and oncologic contexts, searching PubMed and Scopus from January 1990 to June 2026 and extending the search for the historical literature. In CVD, CERT and CERT2 predicted cardiovascular events and mortality independently of LDL cholesterol, including in statin-treated and kidney disease populations. In metabolic and autoimmune rheumatic disease, ceramide profiles tracked cardiovascular risk and disease activity. In inflammatory bowel disease, chronic obstructive pulmonary disease, and most cancers, the evidence is mechanistically strong but limited to single-cohort or observational studies. Ceramides are emerging biomarkers that complement, not replace, established risk tools. Broader clinical use requires prospective validation, diverse cohorts, standardized assays, and demonstrated cost-effectiveness.
Related
- Role of 12/15-lipoxygenase and its metabolites in cardiovascular diseases
- Crosstalk between ubiquitination and other post-translational modifications in cardiovascular diseases.
- Extracellular Mitochondrial Components as Emerging Biomarkers and Therapeutic Targets in Human Diseases.
- Molecular mechanisms, crosstalk and therapeutic potential of novel acylation modifications in cardiovascular and cerebrovascular diseases.
- Dickkopf-3 (DKK3) in cardiovascular diseases: from a stress-responsive biomarker to a potential therapeutic target
BibTeX
@article{garikipati2026ceramides,
title = {{Ceramides as Biomarkers of Risk Prediction and Prognosis in Cardiovascular and Other Diseases: Are We There Yet?}},
author = {Thansi Garikipati and Priya Dubey and Dylan Work and Sanidhya Oli and Dhruv Akhilesh Sharma and Subroto Chatterjee},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27219605},
url = {https://www.mdpi.com/1422-0067/27/21/9605},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Ceramides as Biomarkers of Risk Prediction and Prognosis in Cardiovascular and Other Diseases: Are We There Yet?
AU - Thansi Garikipati
AU - Priya Dubey
AU - Dylan Work
AU - Sanidhya Oli
AU - Dhruv Akhilesh Sharma
AU - Subroto Chatterjee
PY - 2026
DA - 2026/10/27
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27219605
UR - https://www.mdpi.com/1422-0067/27/21/9605
AB - Cardiovascular disease (CVD) is the leading cause of death worldwide, yet roughly 70% of major adverse cardiovascular events occur in statin-treated patients with optimized Low-density lipoprotein cholesterol (LDL-C), a gap that cholesterol-based risk panels do not close. Ceramides are bioactive sphingolipids whose plasma species and ratios carry risk information absent from standard lipid panels, and ceramide-based scores (CERT and CERT2) are already in clinical use. Whether this value extends beyond CVD is unclear. We reviewed ceramide species and ratios as biomarkers for disease prediction, prognosis, and disease activity across cardiovascular, metabolic, autoimmune rheumatic, inflammatory bowel, pulmonary, kidney, and oncologic contexts, searching PubMed and Scopus from January 1990 to June 2026 and extending the search for the historical literature. In CVD, CERT and CERT2 predicted cardiovascular events and mortality independently of LDL cholesterol, including in statin-treated and kidney disease populations. In metabolic and autoimmune rheumatic disease, ceramide profiles tracked cardiovascular risk and disease activity. In inflammatory bowel disease, chronic obstructive pulmonary disease, and most cancers, the evidence is mechanistically strong but limited to single-cohort or observational studies. Ceramides are emerging biomarkers that complement, not replace, established risk tools. Broader clinical use requires prospective validation, diverse cohorts, standardized assays, and demonstrated cost-effectiveness.
SN - 1422-0067
ER -